Finch transfers FIN-524 ulcerative colitis program to Takeda for clinical development

Finch Therapeutics Group, Inc.

Amendment (Aug 9, 2021) transfers primary development & regulatory responsibility for FIN-524/TAK-524 to Takeda ahead of Phase 1.
Finch received $10M upfront & $4M in milestones; eligible for up to $176M additional plus mid-to-high single-digit royalties.
Finch will provide technical support through Phase 1; joint Crohn's disease discovery continues.
TAK-524 is an orally administered consortia candidate targeting ulcerative colitis via immune modulation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.